yingweiwo

Wnt

Wnt

Wnt related products

Structure Cat No. Product Name CAS No. Product Description
21H7 V104745 21H7 217317-45-8 21H7 is a selective inhibitor of the Wnt/b-catenin pathway.
3289-8625 V102465 3289-8625 294891-81-9 3289-8625 is an inhibitor of the PDZ domain of Dishevelled (Dvl) protein (Kd=10.6 μM), which inhibits Wnt signaling.
4,4'-Di-O-methylellagic acid (4,4'-DiOMEA; Nasutin C) V84636 4,4'-Di-O-methylellagic acid (4,4'-DiOMEA; Nasutin C) 3374-77-4
8BTC V80838 8BTC 8BTC (compound 4w) is a potent covalent Notum inhibitor (antagonist) with IC50 of 2.5 nM.
ABC99 V69164 ABC99 2331255-53-7 BC99 is an N-hydroxyhydantoin (NHH) carbamate that selectively inhibits the Wnt-deacylating enzyme NOTUM (IC50=13 nM).
AMG-167 V128677 AMG-167 1798349-30-0 AMG-167 is an anticancer monoclonal antibody that targets bone protein.
Antiproliferative agent-76 V129151 Antiproliferative agent-76 33757-62-9 Antiproliferative agent-76 is an 8-sulfonamide quinoline derivative and a selective anticancer agent.
APD-94 V129223 APD-94 877810-03-2 APD-94 is a dual inhibitor that targets both tubulin and Bmi-1.
AZD8701 sodium scrambled negative control V129727 AZD8701 sodium scrambled negative control The AZD8701 sodium scrambled negative control is a negative control with the sequence of AZD8701 sodium salt scrambled.
BCN512 V129941 BCN512 346691-54-1 BCN512 is an SFRP1 inhibitor that can inhibit tissue fibrosis.
BMD4503-1 V130390 BMD4503-1 301357-76-6 BMD4503-1 is a quinoxaline derivative.
Box5 V69166 Box5 1206604-29-6 Box5 is a potent Wnt5a antagonist.
Box5 TFA V77189 Box5 TFA Box5 TFA is a potent Wnt5a antagonist.
C1s Enzyme V88134 C1s Enzyme C1s Enzyme is a subunit of the complement C1 complex and can activate complement as a serine protease.
Carboxylesterase-IN-3 V69165 Carboxylesterase-IN-3 2764748-92-5 Carboxylesterase-IN-3 (compound 4y) is a potent Carboxylesterase Notum inhibitor (antagonist) with IC50 less than or equal to 10 nM.
Cardionogen 1 (CDNG1/vuc230) V69169 Cardionogen 1 (CDNG1/vuc230) 577696-37-8 Cardionogen 1 (CDNG1/vuc230) is a Wnt signaling pathway inhibitor that can slow down Myc-induced liver tumorigenesis.
Cardionogen-2 V131068 Cardionogen-2 578755-52-9 Cardionogen-2 is a biphasic regulator of cardiac development; depending on the stage of treatment, it can either promote or inhibit cardiac formation.
CCT070535 V98449 CCT070535 485319-41-3 CCT070535 blocks TCF-dependent transcription at the TCF level, with GI50 values of 17.6 μM, 11.1 μM, 11.8 μM, and 13.4 μM in HT29 (APC mutation), HCT116 (oncogenic β-catenin), SW480 (APC mutation), and SNU475 (Axin mutation) cells, respectively.
Chikusetsusaponin IVa methyl ester V131499 Chikusetsusaponin IVa methyl ester 58546-61-5 Chikusetsusaponin IVa methyl ester is a natural triterpenoid saponin compound.
Cibotercept V131696 Cibotercept 2769700-97-0 Cibotercept is a novel, modified, investigational activin receptor type IIB (ActRIIB) ligand trap designed to target specific TGF-β ligands, including activins A and B, GDF 8 and 11, to rebalance the activin receptor type II signaling defects observed in PAH.
Contact Us